Immatics N.V.
IMTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. At a $1.44B market cap, Immatics N.V. ranks as a small-cap company within healthcare. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Market Cap
$1.44B
Beta
1.33
P/E (TTM)
—
P/E (Fwd)
-4.57
EPS (TTM)
$-1.84
EPS (Fwd)
$-2.07
ROE
-47.8%
ROA
-26.9%
Cash
$393.4M
Total Debt
$14.6M
Free CF
-$126.5M
52W Change
64.5%
Annual Financials
Cash vs Debt
Where IMTX stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, IMTX finished 4.70% below its 150-day moving average ($10.00) and 4.99% below its 200-day moving average ($10.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMTX overbought or oversold?
At the September 1, 2026 close, IMTX's RSI(14) was 46.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $393.4M in cash and $14.6M in debt, IMTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$126.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -47.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $172.8M (2022) to $48.3M (2025), a 72% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Immatics N.V. and its sector.